Neurocrine Biosciences (NBIX) Misses Q3 EPS by 8c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. WDC
2. DECK
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. TSCO
9. WCN
10. KNSL

Go back to Neurocrine Biosciences (NBIX) Misses Q3 EPS by 8c, Revenues Beat

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

November 4, 2019 4:01 PM EST

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.

"We are pleased that a record number of new patients initiated treatment with INGREZZA as healthcare providers continue... More